Asset Management One
AKBA icon

Asset Management One’s Akebia Therapeutics AKBA Stock Holding History

Asset Management One’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-23,940
Closed -$370K – 1080
2017
Q4 		$370K Buy
+23,940
New +$397K ﹤0.01% 945

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Asset Management One's AKBA Position: Q1 2018 in Review

Asset Management One sold out of Akebia Therapeutics (AKBA) in Q1 2018, closing a stake of 23,940 shares — an estimated $370K sold.

Asset Management One first reported a position in AKBA in Q4 2017 and held it in 1 quarter. The position peaked at $370K in Q4 2017. 153 funds tracked by Wall St. Rank hold AKBA as of Q1 2018.

  • Asset Management One reported no remaining Akebia Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Asset Management One sold 23,940 Akebia Therapeutics shares in Q1 2018, an estimated $370K.
  • Asset Management One first reported a position in Akebia Therapeutics in Q4 2017 and held it in 1 quarter.
  • Asset Management One's Akebia Therapeutics position peaked at $370K in Q4 2017.
  • 153 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2018.

Based on Asset Management One's 13F filing for Q1 2018, filed 14 May 2018.